Literature DB >> 33942202

Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.

Chen Xiong1, Zhihuai Wang1, Guifu Wang1, Chi Zhang2, Shengjie Jin2, Guoqing Jiang2, Dousheng Bai3.   

Abstract

Hepatocellular carcinoma (HCC) is a malignancy with a poor prognosis. E3 ubiquitin-protein ligases play essential roles in HCC, such as regulating progression, migration, and metastasis. We aimed to explore a hub E3 ubiquitin-protein ligase gene and verify its association with prognosis and immune cell infiltration in HCC. Cell division cycle 20 (CDC20) was identified as a hub E3 ubiquitin-protein ligase in HCC by determining the intersecting genes in a protein-protein interaction (PPI) network of differentially expressed genes (DEGs) using HCC data from the International Cancer Genome Consortium (ICGC) and the gene list of 919 E3 ubiquitin-protein ligases. DEGs and their correlations with clinicopathological features were explored in The Cancer Genome Atlas (TCGA), ICGC, and Gene Expression Omnibus (GEO) databases via the Wilcoxon signed-rank test. The prognostic value of CDC20 was illustrated by Kaplan-Meier (K-M) curves and Cox regression analyses. Subsequently, the correlation between CDC20 and immune infiltration was demonstrated via the Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA). CDC20 expression was significantly higher in HCC than in normal tissues (all P < 0.05). High CDC20 expression predicted a poor prognosis and might be an independent risk factor in HCC (P < 0.05). Additionally, CDC20 was correlated with the immune infiltration of CD8 + T cells, T cells (general), monocytes, and exhausted T cells. This study reveals the potential prognostic value of CDC20 in HCC and demonstrates that CDC20 may be an immune-associated therapeutic target in HCC because of its correlation with immune infiltration.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CDC20; E3 ubiquitin-protein ligase; hepatocellular carcinoma; immune infiltration; prognosis

Mesh:

Substances:

Year:  2021        PMID: 33942202     DOI: 10.1007/s10637-021-01126-1

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  47 in total

Review 1.  Hepatocellular Carcinoma.

Authors:  Augusto Villanueva
Journal:  N Engl J Med       Date:  2019-04-11       Impact factor: 91.245

Review 2.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Authors:  Geoffrey T Gibney; Louis M Weiner; Michael B Atkins
Journal:  Lancet Oncol       Date:  2016-12       Impact factor: 41.316

Review 3.  Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.

Authors:  Li Yang; Jing Chen; Xi Huang; Enfan Zhang; Jingsong He; Zhen Cai
Journal:  Am J Med Sci       Date:  2017-12-28       Impact factor: 2.378

Review 4.  E3 ubiquitin ligases in cancer and implications for therapies.

Authors:  Dong Wang; Leina Ma; Bin Wang; Jia Liu; Wenyi Wei
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

Review 5.  The Basis of Oncoimmunology.

Authors:  A Karolina Palucka; Lisa M Coussens
Journal:  Cell       Date:  2016-03-10       Impact factor: 41.582

Review 6.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.

Authors:  Sandip Pravin Patel; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2015-02-18       Impact factor: 6.261

7.  Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.

Authors:  Yutaka Kurebayashi; Hidenori Ojima; Hanako Tsujikawa; Naoto Kubota; Junki Maehara; Yuta Abe; Minoru Kitago; Masahiro Shinoda; Yuko Kitagawa; Michiie Sakamoto
Journal:  Hepatology       Date:  2018-07-25       Impact factor: 17.425

Review 8.  Targeting SCF E3 Ligases for Cancer Therapies.

Authors:  Jing Liu; Yunhua Peng; Jinfang Zhang; Jiangang Long; Jiankang Liu; Wenyi Wei
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  Multi-omics Analysis of Microenvironment Characteristics and Immune Escape Mechanisms of Hepatocellular Carcinoma.

Authors:  Wenli Li; Huimei Wang; Zhanzhong Ma; Jian Zhang; Wen Ou-Yang; Yan Qi; Jun Liu
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

10.  Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis.

Authors:  Rongkun Li; Yahui Wang; Xiaoxin Zhang; Mingxuan Feng; Jun Ma; Jun Li; Xiaomei Yang; Fang Fang; Qiang Xia; Zhigang Zhang; Mingyi Shang; Shuheng Jiang
Journal:  Mol Cancer       Date:  2019-01-31       Impact factor: 27.401

View more
  3 in total

Review 1.  CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies.

Authors:  Samantha Bruno; Andrea Ghelli Luserna di Rorà; Roberta Napolitano; Simona Soverini; Giovanni Martinelli; Giorgia Simonetti
Journal:  J Exp Clin Cancer Res       Date:  2022-04-30

2.  ASPM Is a Prognostic Biomarker and Correlates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma.

Authors:  Tingting Deng; Yang Liu; Jialang Zhuang; Yizhe Tang; Qin Huo
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

3.  A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.

Authors:  Yuliang Wang; Jiaqi Fan; Tao Chen; Lele Xu; Pengyu Liu; Lijia Xiao; Tao Wu; Qingchun Zhou; Qingyou Zheng; Chunxiao Liu; Franky Leung Chan; Dinglan Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-10       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.